Trevi Therapeutics Files 8-K on Operations and Financials
Ticker: TRVI · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1563880
Sentiment: neutral
Topics: operations, financials, reporting
TL;DR
Trevi Therapeutics dropped an 8-K on Jan 8th - check financials and operations updates.
AI Summary
On January 8, 2025, Trevi Therapeutics, Inc. filed an 8-K report detailing significant corporate events. The filing indicates the company is providing updates on its results of operations and financial condition, alongside other material events and financial statements. This report is crucial for investors to understand the company's current standing and recent developments.
Why It Matters
This 8-K filing provides investors with essential, up-to-date information on Trevi Therapeutics' financial health and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- January 8, 2025 (date) — Date of earliest event reported
- 195 Church Street, 16th Floor, New Haven, Connecticut 06510 (address) — Principal Executive Offices
- 203-304-2499 (phone_number) — Registrant's telephone number
FAQ
What specific "Results of Operations and Financial Condition" are being reported by Trevi Therapeutics?
The 8-K filing indicates that Trevi Therapeutics is reporting on its Results of Operations and Financial Condition, but the specific details are not provided in the provided text excerpt. Further review of the full filing would be necessary to ascertain these details.
What are the 'Other Events' mentioned in the 8-K filing?
The filing states that 'Other Events' are being reported, but the nature of these events is not specified in the excerpt. The full document would contain this information.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on January 8, 2025.
What is Trevi Therapeutics' principal executive office address?
Trevi Therapeutics' principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
What is the Commission File Number for Trevi Therapeutics?
The Commission File Number for Trevi Therapeutics is 001-38886.
Filing Stats: 1,109 words · 4 min read · ~4 pages · Grade level 14 · Accepted 2025-01-08 08:00:09
Key Financial Figures
- $0.001 — e on which registered Common stock, $0.001 par value per share TRVI The Nasdaq
- $107.6 million — valents, and marketable securities were $107.6 million as of December 31, 2024. The full text
Filing Documents
- trvi-20250108.htm (8-K) — 56KB
- trvi-ex99_1.htm (EX-99.1) — 25KB
- img251553556_0.jpg (GRAPHIC) — 29KB
- 0000950170-25-003286.txt ( ) — 244KB
- trvi-20250108.xsd (EX-101.SCH) — 28KB
- trvi-20250108_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On January 8, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release providing company updates in advance of its participation in the 14th Annual LifeSci Partners Corporate Access Event taking place in San Francisco, California from January 13 to 15, 2025, during the week of the annual J.P. Morgan Healthcare Conference (the "Release"). In the Release, the Company announced that it estimates its cash, cash equivalents, and marketable securities were $107.6 million as of December 31, 2024. The full text of the Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company's estimate of its cash, cash equivalents, and marketable securities as of December 31, 2024 is a preliminary estimate based on information available as of the date of this Current Report on Form 8-K, and its actual cash, cash equivalents, and marketable securities may be different from this preliminary estimate. In addition, the Company's independent registered public accounting firm has not audited or reviewed this preliminary estimate. The information provided under Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events The company updates in the Release include: Phase 2a RIVER Trial The last patient completed their final visit in the Company's Phase 2a RIVER trial in refractory chronic cough, which was designed to enroll approximately 60 patients, at the beginning of January 2025. Topline results for the trial continue to be expected in the first quarter of 2025. Phase 2b CORAL Trial The positive outcome for the sample size re-estimation analysis for the Company's Phase 2b CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough was announced in December 2024, reaffirming the original sample size for the trial (N=160). The trial is now approximately 80% enrolled and topline results continue to be expected in the first half of 2025.
Forward-Looking Statements
Forward-Looking Statements
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on January 8, 2025 * 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The exhibit shall be deemed to be furnished, and not filed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREVI THERAPEUTICS, INC. Date: January 8, 2025 By: /s/ Lisa Delfini Name: Lisa Delfini Title: Chief Financial Officer